| abstract |
The present invention relates to [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionic acid-(S)-3'-methanol The innovative crystal form of yl-2'-(pentanoyl {2”-(tetrazol-5-yl)biphenyl-4’-ylmethyl}amino)butanoic acid] trisodium salt hydrate, the preparation of the new crystal form Method, the pharmaceutical composition comprising these new crystal forms, and its use in the treatment or delay of diseases such as heart failure related to the activity of angiotensin receptor 1 (AT1) blocking action and neprilysin (NEP) inhibitory action or Use during exacerbation or flare-ups of a disorder. |